A rare autoimmune disorder popularized by the autobiography and movie "Brain on Fire" is triggered by an attack on NMDA receptors. The disease occurs when antibodies attack NMDA receptors in the brain, leading to memory loss, intellectual changes, seizures, and death.
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant like ketamine. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say NIH researchers.
in a mouse model of Rett syndrome, researchers were able to reverse abnormalities in brain activity and improve neurological function by treating animals with an FDA-approved anesthesia drug, ketamine.
Brain connections strengthened with treatment from fast-acting antidepressants, such as ketamine, are consolidated during deep sleep. Researchers propose rapid antidepressant treatments share the ability to regulate both synaptic potentiation and homeostatic mechanisms, which may contribute to how the brain reorganizes its activity to defeat depression.
A new study looks at the role glutamate plays in neuromuscular development.
Researchers have identified a mechanism which triggers the disruption in the brain's communication channels that occurs in schizophrenia.
Researchers uncover clues about the biochemical pathway in the brain which could expand treatment options for schizophrenia.
Researchers discover a protein switch which can increase or decrease memory building, depending on the signal it detects.